XinliTai Announces Clinical Trial Approval for SAL0167 Tablet in Hyperlipidemia Treatment

(Source: Caiwen)

The Company received the “Notice of Approval for Clinical Trials” approved and issued by the National Medical Products Administration, agreeing to conduct clinical trials on hyperlipidemia for SAL0167 tablets, an innovative drug independently developed by the Company.

July 8,Salubris（002294.SZ）The announcement stated that the Company received the "Notice of Approval for Clinical Trials" approved and issued by the National Medical Products Administration, agreeing to conduct clinical trials of SAL0167 tablets, an innovative drug independently developed by the Company, for hyperlipidemia.

SAL0167 is a cyclic peptide drug with independent intellectual property rights developed by the Company. It has the potential to become the preferred treatment option for patients with hypercholesterolemia requiring potent lipid-lowering therapy, thereby providing new therapeutic choices for patients and enriching the Company’s innovative product pipeline in the field of chronic diseases.